Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L*, Goodrich DW* (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. *Co-corresponding author. Science (2017).
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (2017).
Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research (2017).
Pomerantz M, Qui X, Zhu Y, Takeda D, Korthauer K, Baca S, Gusev A, Severson T, Ha G, Srinivas V, Seo J, Nguyen H, Pasaniuc B, Giambartolomei C, Abou Alaiwi S, Bell C, O’Connor E, Chabot M, Stillman D, Font-Tello A, Li L, Cejas P, Bergman A, van der Poel H, Gayther S, Lawrenson K, Abraao M, Reddy J, Corona I, Martovetsky G, Egan B, Ellis L, Corey E, Long H, Zwart W, Pan W, Gwo-Shu ML, Lis R, Zhang B, Garraway I, Choueiri T, Sander J, Freedman ML. Prostate Cancer Reactivates Developmental Epigenomic Programs during Metastatic Progression. Nature Genetics (2020).
Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, Xu B, Loda M, Ellis L. Evidence that Ezh2 Dysregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prevention Research (2020). Selected for December Issue 2020 Cover Art.
Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Lui Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky A, He HH, Freedman ML, Balk SP, Loda M, Labbé DP, Olson BM, Ellis L. EZH2 Inhibition Activates a dsRNA-STING-Interferon Axis that Potentiates Response to PD-1 Check-Point Blockade in Prostate Cancer. Nature Cancer (2021).
Morel KL, Hamid AA, Clohessy JG, Pandell N, Ellis L, Sweeney CJ. NF-kB Blockade with Oral Administration of Dimethylaminoparthenolide Delays Prostate Cancer Resistance to Androgen Receptor Inhibition and Inhibits AR Variants. Molecular Cancer Research (2021).
German B, Ellis L. Polycomb Directed Cell Fate Decisions in Development and Cancer. Epigenomes. (2022).
German B, Nanda JS, Fonseca MAdS, Burkhart DL, Sheahan A, Bergom H, Morel KL, Beltran H, Hwang JH, Lawrenson K, Ellis L. MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. Cancer Research Communications (2024).
Morel KL, German B, Hamid AA, Singh JN, Linder S, Berger AM, van der Poel H, Bekers EM, Trostel SY, Burkhart DL, Wilkinson S, Ku AT, Kim M, KimJ, Ma D, Plummer JT, You S, Su XA, Zwart W, Sowalsky AG, Sweeney CJ, Ellis L. Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice. Journal of Clinical Investigation (2024).